120 related articles for article (PubMed ID: 2950328)
1. GBR 13098, a selective dopamine uptake inhibitor; behavioural, biochemical and electrophysiological studies.
Pileblad E; Engberg G
Naunyn Schmiedebergs Arch Pharmacol; 1986 Dec; 334(4):383-7. PubMed ID: 2950328
[TBL] [Abstract][Full Text] [Related]
2. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra.
Nissbrandt H; Engberg G; Pileblad E
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):16-28. PubMed ID: 1663587
[TBL] [Abstract][Full Text] [Related]
3. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
Engberg G; Elebring T; Nissbrandt H
J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
[TBL] [Abstract][Full Text] [Related]
4. The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
Andersen PH
Eur J Pharmacol; 1989 Aug; 166(3):493-504. PubMed ID: 2530094
[TBL] [Abstract][Full Text] [Related]
5. Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake.
Heikkila RE; Manzino L
Eur J Pharmacol; 1984 Aug; 103(3-4):241-8. PubMed ID: 6237922
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of the ambulation-increasing effect of GBR-12909, a selective dopamine uptake inhibitor, in mice.
Hirate K; Kuribara H
Jpn J Pharmacol; 1991 Apr; 55(4):501-11. PubMed ID: 1832199
[TBL] [Abstract][Full Text] [Related]
7. Effects of GBR 12909, a selective dopamine uptake inhibitor, on motor activity and operant behavior in the rat.
Kelley AE; Lang CG
Eur J Pharmacol; 1989 Aug; 167(3):385-95. PubMed ID: 2530095
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of dopamine re-uptake: significance for nigral dopamine neuron activity.
Engberg G; Elverfors A; Jonason J; Nissbrandt H
Synapse; 1997 Feb; 25(2):215-26. PubMed ID: 9021902
[TBL] [Abstract][Full Text] [Related]
9. Cross-sensitization between cocaine and GBR 12909, a dopamine uptake inhibitor.
Baldo BA; Kelley AE
Brain Res Bull; 1991 Jul; 27(1):105-8. PubMed ID: 1834316
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of the discriminative-stimulus effects of GBR 12909.
Melia KF; Spealman RD
J Pharmacol Exp Ther; 1991 Aug; 258(2):626-32. PubMed ID: 1678014
[TBL] [Abstract][Full Text] [Related]
11. Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.
Svensson K; Ekman A; Piercey MF; Hoffmann WE; Lum JT; Carlsson A
Naunyn Schmiedebergs Arch Pharmacol; 1991 Sep; 344(3):263-74. PubMed ID: 1683686
[TBL] [Abstract][Full Text] [Related]
12. GBR 12909 fails to antagonize cocaine-induced elevation of dopamine in striatal slices.
Gifford AN; Bergmann JS; Johnson KM
Drug Alcohol Depend; 1993 Mar; 32(1):65-71. PubMed ID: 8486086
[TBL] [Abstract][Full Text] [Related]
13. Mediation of dopamine D1 and D2 receptors in the effects of GBR 12909 on latent learning and locomotor activity in mice.
Ichihara K; Nabeshima T; Kameyama T
Eur J Pharmacol; 1993 Apr; 234(2-3):155-63. PubMed ID: 8097720
[TBL] [Abstract][Full Text] [Related]
14. [3H]GBR 12935 binding to human platelet membranes is sensitive to piperazine derivatives but not to dopamine uptake inhibitors.
Gordon I; Weizman R; Rehavi M
Life Sci; 1994; 55(3):189-99. PubMed ID: 8007761
[TBL] [Abstract][Full Text] [Related]
15. The selective dopamine uptake inhibitor GBR 12909: its effects on the microstructure of feeding in rats.
van der Hoek GA; Cooper SJ
Pharmacol Biochem Behav; 1994 May; 48(1):135-40. PubMed ID: 8029284
[TBL] [Abstract][Full Text] [Related]
16. Effects of amfonelic acid and GBR 12909 on the haloperidol- and clozapine-induced activation of dopamine neurons.
Gudelsky GA; Nwajei EE; Defife K; Nash JF
Psychopharmacol Bull; 1992; 28(3):275-9. PubMed ID: 1480731
[TBL] [Abstract][Full Text] [Related]
17. Dopamine uptake inhibition potentiates the effects of L-DOPA on rat substantia nigra zona compacta neurons.
Mercuri NB; Calabresi P; Bernardi G
Neurosci Lett; 1991 May; 126(1):79-82. PubMed ID: 1830942
[TBL] [Abstract][Full Text] [Related]
18. [The effect of the dopamine neuronal reuptake inhibitor GBR 12909 on the dopaminergic neurotransmission parameters in the rat striatum in vivo].
Budygin EA; Kilpatrick M; Gaĭnetdinov RR; Raevskiĭ KS; Wightman RM
Eksp Klin Farmakol; 1999; 62(5):3-6. PubMed ID: 10572741
[TBL] [Abstract][Full Text] [Related]
19. Effects of benztropine on behavioral and toxic effects of cocaine: comparison with atropine and the selective dopamine uptake inhibitor 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-propyl)-piperazine.
Acri JB; Siedleck BK; Witkin JM
J Pharmacol Exp Ther; 1996 Apr; 277(1):198-206. PubMed ID: 8613919
[TBL] [Abstract][Full Text] [Related]
20. Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine.
Jackson DM; Martin LP; Larsson LG; Cox RF; Waszczak BL; Ross SB
Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep; 342(3):290-9. PubMed ID: 2126347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
